MP
Michael Pulsipher
Huntsman Cancer Institute, Children's Hospital Los Angeles Children's Center for Cancer and Blood Diseases, Dana-Farber Cancer Institute, Children's Hospital of Philadelphia, University of Utah
Research areas: Medicine · Hematology · Hematopoietic Stem Cell Transplantation · Transplantation: Methods and Outcomes · Immunodeficiency and Autoimmune Disorders
0000-0003-3030-8420
Employment
-
University of Utah Health Huntsman Cancer Institute Division Chief, Pediatric Hematology and Oncology2021 - Present
-
Children's Hospital Los Angeles Children's Center for Cancer and Blood Diseases Section Head, Transplantation and Cellular Therapy2015 - 2021
-
The University of Utah Professor/Clinician Scholar Tenure Track2000 - 2015
-
Dana Farber Cancer Institute Instructor1996 - 1998
Education
-
Dana Farber Cancer Institute Fellowship1993 - 1996
-
Children's Hospital of Philadelphia Pediatric Residency1990 - 1993
- 1986 - 1990
Projects & Funding
Projects & funding information is unavailable.
Publications (31)
- CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multisite, retrospective cohort review Save
- Refractory infantile IPEX with Treg-restricted FOXP3null expression caused by a novel variant in FOXP3 Save
- Boosting the Predictive Power of Virus-Specific T-Cell Clinical Trials via Generative Models Save
- Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL Save
- Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALL Save
- Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALL Save
- Low counts count after CAR-T for ALL Save
- Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy Save
- A better approach to mismatched HSCT than PTCY? Save
- How I use next-generation sequencing–MRD to plan approach and prevent relapse after HCT for children and adults with ALL Save
- Long-term Outcomes of Peripheral Blood Stem Cell Unrelated Donors Mobilized with Filgrastim Save
- INSPIRED Symposium Part 2: Prevention and Management of Relapse Following Chimeric Antigen Receptor T Cell Therapy for B Cell Acute Lymphoblastic Leukemia Save
- INSPIRED Symposium Part 1: Clinical Variables Associated with Improved Outcomes for Children and Young Adults treated with Chimeric Antigen Receptor T cells for B cell Acute Lymphoblastic Leukemia Save
- Introduction to the Reports from the Insights in Pediatric CAR T-cell Immunotherapy: Recent Advances and Future Directions (INSPIRED) Symposium Save
- Blinatumomab Conundrum in Low-Risk Relapsed B-Cell ALL Save
- Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT Save
- Venetoclax and Azacitidine in the Treatment of NPM1-Mutated Donor Cell–Derived Leukemia in a Patient With Fanconi Anemia: Case Report and Literature Review Save
- How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL Save
- KIR-favorable TCR-αβ/CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial Save
- Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma Save